Active Ingredient History
Semustine is an alkylating nitrosourea compound used in chemotherapy treatment of various types of tumours. Due to its lipophilic property, semustine can cross the blood-brain barrier for the chemotherapy of brain tumours, where it interferes with DNA replication in the rapidly-dividing tumour cells. Semustine, just as lomustine, is administered orally. Evidence has been found that treatment with semustine can cause acute leukaemia as a delayed effect in very rare cases. Wikipedia
Organization | Org Type | FDA approvals | Clinical Trials involvement | Org ID | Force Sort |
---|
Organization | Org Type | FDA approvals | Clinical Trials involvement | Org ID | Force Sort |
---|
Astrocytoma (Phase 3)
Colorectal Neoplasms (Phase 3)
Glioblastoma (Phase 3)
Graft vs Host Disease (Phase 3)
Hematopoietic Stem Cell Transplantation (Phase 2/Phase 3)
Leukemia (Phase 3)
Leukemia, Myeloid, Acute (Phase 2/Phase 3)
Lymphoma, T-Cell, Peripheral (Phase 3)
Recurrence (Phase 3)
Vascular Grafting (Phase 3)
Trial | Phase | Start Date | Organizations | Indications |
---|
Feedback
Data collection and curation is an ongoing process for CDEK - if you notice any information here to be missing or incorrect, please let us know! When possible, please include a source URL (we verify all data prior to inclusion).
Report issue